Showing results (121-130 of 297) with videos related to
Sort By:
Pageof 30
Breast Care (Basel, Switzerland)|October 9, 2025
New Perspectives in the Management of Triple-Negative Breast CancerRupert Bartsch, Zsuzsanna Bago-Horvath, Daniel Egle, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancerWolfgang J Köstler, Barbara Schwab, Christian F Singer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy OnlyMartin Filipits, Peter Dubsky, Margaretha Rudas, et al.Wiener Klinische Wochenschrift|April 3, 2023
Axillary lymph node status and invasive lobular breast cancer : Analysis of the Clinical Tumor Register of the AGO AustriaSabine Danzinger, Karin Pöckl, Gerit Kronawetter, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trialErnst Kubista, Juan V M Planellas Gomez, Mitch Dowsett, et al.Journal of Cancer Research and Clinical Oncology|May 3, 2005
The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 statusWolfgang J Köstler, Thomas Brodowicz, Gernot Hudelist, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2011
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancerZsuzsanna Bago-Horvath, Margaretha Rudas, Peter Dubsky, et al.Breast (Edinburgh, Scotland)|January 7, 2026
HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trialChristian F Singer, Franz Koenig, Stephanie Kacerovsky-Strobl, et al.International Journal of Cancer|January 14, 2018
The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriersKwang-Pil Ko, Shana J Kim, Tomasz Huzarski, et al.Breast Cancer Research and Treatment|January 31, 2012
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II studyIrene Kuter, Julia M W Gee, Roberto Hegg, et al.Pageof 30